1999 April 16, the front page of The Wall Street Journal reported "Initiating a New Era of Individualized Drug Therapy —— Determining Drug Category and Dosage according to Individual Genotype", which keenly proposed the arrival of a new era of gene-oriented individualized drug therapy to the world. On March 22, 2005, the US Food and Drug Administration (FDA) issued a "drug genome data submission" guide for pharmaceutical companies. The purpose of this guide is to urge pharmaceutical companies to provide pharmacogenomic data of new drugs according to specific conditions when submitting new drug applications. Its purpose is to promote a more effective new "individualized medication" process, and finally use drugs according to "everyone's genetic status", so that patients can get the maximum drug efficacy and only face the minimum risk of adverse drug reactions. The new guidelines issued by FDA undoubtedly sounded the clarion call for human beings to March into "individualized medication based on pharmacogenomics".
The history of individualized medication in China, 200 1 year, successfully developed the world's first "gene chip for individualized medication of hypertension" for specific diseases. Individualized medication guidance and consultation center was established in 2004, individualized therapy gene analysis center was established in 2006, and Xiangya Medical Laboratory of Central South University was established on 20/0/0. The medical research results of "individualized medication" go out of the boudoir, so that more patients can achieve the effect of rational medication.